GLP-1 Check — India's GLP-1 Information & Self-Assessment Tool
All Semaglutide Brands India
Generic SemaglutideType 2 Diabetes + Obesity
Alkem Laboratories logo

Semasize/ Obesema / HepaglideGeneric semaglutide for type 2 diabetes + obesity in India 2026

by Alkem Laboratories · ₹1,800–3,500/month · DCGI approved March 2026

Active ingredient
Semaglutide (GLP-1 receptor agonist)
Indication
Type 2 Diabetes + Obesity
Manufacturer
Alkem Laboratories Ltd
DCGI status
Approved March 2026
Price (MRP)
₹1,800–3,500/month
Lowest-priced prefilled pen semaglutide in India — ₹1,800/month for the T2D starting dose
Format
Prefilled pen
Prescription
Schedule H — required

How Semasize compares

Semasize is Alkem's prefilled-pen semaglutide and the lowest-priced pen format on the Indian market — making patient self-administration affordable in a way the cheaper vial-only options (SUNDAE) cannot. Obesema and Hepaglide are Alkem's sister brand names for distinct prescribing channels.

About Alkem Laboratories

Alkem Laboratories is one of India's top-five pharmaceutical companies by domestic sales, with strong franchise positions in anti-infectives and metabolic health. The Semasize pricing strategy — undercutting the Zydus reusable-pen pricing while keeping a familiar disposable-pen format — targets prescribers and patients who prioritise simplicity.

Who is Semasize for?

Semasize is approved in India for both type 2 diabetes and chronic weight management in adults with obesity. Indian guideline eligibility typically requires BMI ≥27.5 (obesity indication) or HbA1c above target on first-line therapy (T2D indication). Patients with BMI ≥25 + comorbidities (PCOS, NAFLD, hypertension, sleep apnea) may also qualify under specialist judgment.

Not sure if you qualify? Take the 5-minute Indian-guideline eligibility check →

Semasize for specific conditions

Semasize for PCOS →Semasize for fatty liver (NAFLD/MASLD) →Semasize for hypertension + obesity →Semasize for sleep apnea + obesity →

Semasize cost in India

MRP for Semasize: ₹1,800–3,500/month. Actual pharmacy pricing varies by city, pharmacy, and channel. Online prescription pharmacies typically offer modest discounts off MRP with cold-chain delivery; hospital pharmacy pricing is usually at MRP.

Compare with all India brands: GLP-1 therapy cost in India 2026 →

Compared to other GLP-1 brands in India

Semasize is an Indian generic semaglutide. Same active molecule as Ozempic and Wegovy (Novo Nordisk innovator brands), with clinical efficacy that follows the molecule rather than the brand. Other Indian generics include Sundae, Noveltreat, Obeda, Semaglyn, Sembolic, and Samakind — all at similar price points.

All GLP-1 comparisons →All Indian semaglutide brands →Clinical evidence library →GLP-1 blog (India) →

Semasize — frequently asked questions

Is Semasize available in India? Is it DCGI-approved?+
Yes — Semasize is DCGI-approved and currently available across India. The drug received DCGI approval in March 2026 for both type 2 diabetes and obesity, manufactured by Alkem Laboratories Ltd. It is distributed through licensed retail and online prescription pharmacies and hospital pharmacies across Indian metros and most tier-2 cities. Semasize is a Schedule H drug — a doctor's prescription is required. Take the GLP-1 Check 5-minute Indian-guideline assessment to see if you qualify.
What does Semasize cost in India in 2026?+
Semasize is priced at ₹1,800–3,500/month (Lowest-priced prefilled pen semaglutide in India — ₹1,800/month for the T2D starting dose). Actual pharmacy pricing may vary by city and channel. For brand-by-brand price comparisons across all India brands, see our cost guide. Take the GLP-1 Check 5-minute Indian-guideline assessment to see if you qualify.
Do I need a prescription to buy Semasize?+
Yes — Semasize is a Schedule H drug in India and can only be dispensed against a valid prescription from a registered medical practitioner. Any legitimate online prescription pharmacy will require you to upload your prescription before order fulfillment.
Who is Semasize for?+
Semasize is approved for both type 2 diabetes and obesity in India. Indian guideline eligibility typically requires BMI ≥27.5 (obesity indication) or HbA1c above target on first-line therapy (T2D indication), often with comorbidities at BMI ≥25. Take the GLP-1 Check 5-minute Indian-guideline assessment to see if you qualify.
How does Semasize compare to Ozempic and Wegovy?+
Semasize contains the same active molecule (semaglutide) as Ozempic and Wegovy. Clinical efficacy is comparable; the difference is brand, manufacturer support, pen design, and price. Semasize (₹1,800–3,500/month) is meaningfully cheaper than Ozempic (₹5,660+/month) or Wegovy (up to ₹16,400/month) — useful for cost-sensitive patients on long-term therapy.
Where can I buy Semasize in India?+
Semasize is a Schedule H drug — available through licensed retail and online prescription pharmacies and hospital pharmacies across India with a doctor's prescription. Always buy from a licensed pharmacy to avoid counterfeit products; never use sources that dispense without verifying a prescription. Take the GLP-1 Check 5-minute Indian-guideline assessment to see if you qualify.
Official

Manufacturer announcement

Alkem Laboratories — Semaglutide Day-1 launch announcement (March 2026)

Additional source

Outlook Business — Alkem semaglutide pricing

GLP-1 Check is informational, not a medical diagnosis. Semaglutide is a Schedule H drug in India and requires a prescription from a registered medical practitioner. Always consult a qualified physician before starting any treatment.

Are you eligible for Semasize?

Take the free 5-minute triage to check your GLP-1 readiness against Indian clinical guidelines.

Check My Eligibility →

Looking at other brands?

See full price comparison across all 25+ DCGI-approved brands →